Premium
Diagnostic Markers in Human Neurooncology A Progress Report a
Author(s) -
RUBINSTEIN LUCIEN J.
Publication year - 1988
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1988.tb27053.x
Subject(s) - neurooncology , context (archaeology) , immunohistochemistry , pathology , medicine , biology , paleontology
In this progress report, some of the most commonly used antibodies are discussed in regard to their immunohistochemical application to human neurooncology. The importance of determining the spectrum of antibody immunoreactivity in a wide panel of normal, reactive, and neoplastic tissues is stressed. in atypical and aberrant cases, immunopositivity needs to be interpreted with caution and in the context of all other available data. The demonstration of a well-characterized, cell type-specific marker in a tumor reflects not so much its cytogenesis as its differentiation potential and its capacity for metaplasia. The relation of an abnormal or aberrant expression of antigenic determinants to the process of neoplasia raises a number of intriguing questions to which research in the next few years will likely provide answers.